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1. Introduction 
The burden of sexually transmitted infections (STIs) on the health and well-being of the 
population in the developing world is considerable. The World Health Organization (WHO) 
estimates that there are 340 million new cases of curable STIs in the world each year; 174 
million new cases of trichomoniasis, 92 million new cases of Chlamydia infection, 62 million 
cases of gonorrhea, and 12 million new cases of syphilis (Table 1). Approximately three 
quarters of these infections are in countries encompassing tropical regions of the world in 
Latin America, sub-Saharan Africa, and South and Southeast Asia. The prevalence of viral 
STIs is even higher; infection with Herpes simplex virus-2 (HSV-2) is the most common STI 
worldwide and as many as 50% of sexually active individuals will be infected with human 
papillomavirus (HPV) during their life. The prevalence of STIs is considerably greater than 
many classical tropical diseases and it is unfortunate that they do not receive more attention 
and resources from international programs and donor groups. The public health impact of 
these diseases extends well beyond the immediate effects and morbidities of infection. STIs 
have been implicated in facilitating acquisition and transmission of HIV, in pregnancy 
complications such as pre-term births, low birth weight infants, stillbirth, neonatal death 
and blindness, in the inducement of cervical and prostate cancers, and in increased risk of 
pelvic inflammatory disease and infertility. Failure to diagnose and treat STIs at an early 
stage thus increases the already substantial burden these conditions impose on the 
populations of developing countries. Although effective diagnostic tests and treatments are 
available for these STIs, they are often unavailable or inaccessible in resource-limited 
tropical settings. As a consequence, syndromic management of STIs remains the option of 
choice for individual case management. The inadequate public health response coupled to 
ongoing socioeconomic and demographic trends have led to an epidemic of STIs in many 
countries in the developing world. The development of antimicrobial resistance is an on-
going problem and new agents are often much more expensive, increasing the burden of 
control. The economic costs of these diseases and their infection sequelae place a 
considerable burden on national health budgets and household income. In developing 
countries, STIs are among the top five reasons for which adults seek medical care. Due to the 
prevalence and public health implications of STIs in the tropics a discussion of STIs should 
be included in any compilation of tropical medicine. 
This chapter will cover sexually transmitted infections caused by Trichomonas vaginalis 
(trichomoniasis), Chlamydia trachomatis (chlamydia and lymphogranuloma venereum), 
Neisseria gonorrhoeae (gonorrhea), Treponema pallidum (syphilis), Haemophilus ducreyi 
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(chancroid), Calymmatobacterium granulomatis (granuloma inguinale or donovanosis), and 
the viral STIs, herpes simplex virus and human papilloma virus. Each of these STIs 
spreads via vaginal, anal, and oral sex, as well as by inoculation of material from infected 
sores in some cases. All share many common risk factors and higher rates of infection are 
seen in marginalized populations; persons of low socioeconomic status, commercial sex 
workers, alcohol abusers, illicit drug users, men who have sex with men, prison 
populations, uncircumcised men, and those with multiple sex partners or who have 
partners with multiple sex partners. This chapter will cover both syndromic management 
of STIs as practiced in most areas of the tropical world (WHO 2003, 2005, 2007b) as well as 
individual descriptions of these diseases, their clinical presentation, diagnosis, and 
treatment. The treatment regimens presented are those recommended by the Centers for 
Disease Control and Prevention (CDC, 2010) and the World Health Organization (WHO, 
2005). 
 
 
Table 1. World Health Organization estimates of new cases of curable sexually transmitted 
infections and HIV, in millions (WHO, 2001; UNAIDS, 2010). 
2. STIs and HIV 
It is estimated that there are 34 million cases of HIV in the world with 68% or 22.5 million 
cases occurring in sub-Saharan Africa, where the prevalence is highest, and 4.1 million in 
South and Southeast Asia. The emergence of the HIV epidemic has complicated the control 
of STIs as HIV induced immunosuppression leads many patients to respond poorly to STI 
treatment regimens, requiring higher drug dosages and longer treatment schedules to affect 
cure. Sexually transmitted infections (STIs) also facilitate the transmission of other STIs, 
including human immunodeficiency virus (HIV). Several observational studies have been 
conducted that conclude there to be a strong association between STI and increased risk of 
HIV acquisition. An individual with a co-existing STI has a 2-5 fold greater risk of acquiring 
and transmitting HIV. Increased risk of HIV transmission has mostly been attributed to 
ulcerative STIs, mainly HSV-1 and 2, but also syphilis, chancroid, lymphogranuloma 
venereum, and granuloma inguinale. For instance the population attributable risk percent of 
HIV acquisition for HSV-1 and 2 varies from 15-30% in Africa. However, studies also show 
that non-ulcerative STIs, gonorrhea, Chlamydia, and trichomoniasis increase the risk of HIV 
transmission and acquisition as well. Studies that have examined non-ulcerative STIs and 
risk of HIV seroconversion have found an odds ratio of 1.8-4.8 for gonorrhea, 1.8-3.6 for 
chlamydia, and 1.9 for trichomoniasis. Therefore, early diagnosis and treatment of treatable 
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STIs could significantly impact the incidence of HIV transmission and acquisition. The 
number of individuals co-infected with HIV and an STI are high. Studies show increases in 
treatment failure of treatable STIs in HIV-positive patients. Studies in several countries 
show high treatment failure of syphilis in HIV-positive patients and in a trichomoniasis 
study, 18% of HIV-positive women were T. vaginalis positive 1 month after treatment. It is 
therefore possible that more aggressive treatment of non-ulcerative STIs may be necessary to 
cure an infection in HIV-positive individuals. STI treatment has been shown to significantly 
reduce HIV-shedding in both men and women. Follow-up for test of cure is also necessary 
due to the higher risk of treatment failure due to co-infection.  
3. Syndromic management 
The diagnosis and management of STIs in the tropics has a dual nature. Sophisticated 
testing equipment and facilities comparable to those available in developed nations can 
often be found in large urban centers and popular resort destinations in developing 
countries. However, in many parts of the developing world, the absence of etiologic 
diagnostic capacity due to constraints imposed by cost, lack of equipment or trained 
personnel, and time management has forced health care providers to rely on a syndrome-
based approach to STI management. This approach employs clinical algorithms based on an 
STI syndrome to determine antimicrobial therapy. The following sections discuss 
management of the most common clinical syndromes encountered in STIs. Sexual partners 
of the index patient should also be examined for STIs and promptly treated for the same 
condition as treatment failures are common when partners are not treated. Often, treatment 
regimens to cover multiple infectious agents are recommended due to the difficulty in 
distinguishing between the overlapping clinical presentations of different STIs, the high 
prevalence of mixed infections in many areas, and to ensure adequate therapy in the case of 
loss to follow-up. Syndromic management enables many STIs to be treated and resolved at 
local clinics which may lack all but the most rudimentary laboratory capabilities. However, 
patients that do not respond to therapy or those that show systemic signs indicative of other 
disease conditions warrant referral to a clinic with more comprehensive facilities.  
3.1 Urethral discharge in men 
Neisseria gonorrhoeae and Chlamydia trachomatis are the major STI pathogens causing urethral 
discharge. In the syndromic management scheme, treatment of men with urethral discharge 
should cover both of these organisms. Treatment regimens may be found in the specific 
sections describing these STIs. Single-dose therapies are preferred. Whenever possible 
microscopic examination of the urethral smear should be performed; the appearance of 
more than 5 polymorphonuclear leukocytes per high power field (x1000) is indicative of 
urethritis. A Gram stain could also demonstrate the presence of gonococci and permit 
specific treatment. Patients should return in 7 days if symptoms persist. Treatment failure 
may be due to drug resistance necessitating use of one of the alternative drugs for these STI 
agents. Patients indicating poor compliance with therapy or the possibility of re-infection 
can be re-treated with the same drug regimen. Trichomonas vaginalis can also be a cause of 
urethritis in men. In areas of high local T. vaginalis prevalence, treatment for this organism 
should also be given at this time. If symptoms still persist, the patient should be referred to a 
facility possessing the resources for a more extensive workup. 
www.intechopen.com
 
Current Topics in Tropical Medicine 460 
3.2 Genital ulcers 
Five STIs typically produce genital ulcers; herpes, syphilis, chancroid, lymphogranuloma 
venereum (LGV), and granuloma inguinale or donovanosis (Table 2). Physical 
examination should focus on the characteristics of the lesion(s): single or multiple, 
painless or painful, indurated or soft, irregular or regular borders, and how they began, as 
a papule or a vesicle. The examination should also determine the time since exposure, the 
presence or absence of lymphadenopathy, and the presence of systemic symptoms which 
may indicate another etiology. Syphilis ulcers are painless, indurated, sharply demarcated 
with a red, smooth base. When present, inguinal adenopathy is firm, rubbery, nontender 
and usually bilateral. Herpes ulcers begin as multiple grouped vesicles on a red base 
which forms shallow ulcers that may coalesce. Herpes inguinal adenopathy is bilateral, 
firm, and tender when present. Chancroid ulcers are shallow and often multiple with 
irregular shape, sharply demarcated borders, and undermined edges. Chancroid inguinal 
adenopathy is typically unilateral, fixed, and tender, with overlying erythema and may 
supperate. Granuloma inguinale ulcers are shallow sharply demarcated lesions with a 
beefy red friable base and usually without inguinal adenopathy. LGV ulcers are usually a 
single lesion, transient, and frequently not noticed. Inguinal adenopathy in LGV is usually 
unilateral, firm, tender, fixed, and may supperate or form fistulas. When genital ulcers 
present as vesicles only, syndromic management recommends treatment for both herpes 
infection and for syphilis if the patient has a positive RPR syphilis test, or has not received 
recent syphilis treatment. Patients with ulcers and no vesicles should be treated for 
syphilis plus either chancroid, granuloma inguinale, or lymphogranuloma venereum 
dependent on clinical presentation and local prevalence of these agents. In areas where 
herpes prevalence exceeds 30%, patients with ulcers should also be treated for herpes. 
Patients whose ulcers do not respond to both initial treatment and follow-up therapy 
should be referred for more extensive diagnostic testing.  
 
 
 
 
Table 2. Characteristics of Genital Ulcers 
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3.3 Inguinal bubo 
Inguinal buboes are frequently associated with LGV and chancroid. If genital ulcers 
accompany the buboes, patients should be managed using the genital ulcer syndromic 
management approach. Inguinal buboes not accompanied by genital ulcer presentation 
should be treated with a regimen effective against LGV and chancroid. The recommended 
syndromic treatment is ciprofloxacin, 500 mg orally twice daily for 3 days plus doxycycline, 
100 mg orally twice daily for 14 days, or erythromycin, 500 mg orally four times daily for 14 
days. Some cases may require longer treatment than 14 days if the buboes are not resolved. 
Fluctuant lymph nodes can be aspirated through healthy skin. Incision and drainage or 
excision of nodes may delay healing. 
3.4 Scrotal swelling 
There are multiple infectious causes for epididymitis as well as non-infectious causes such 
as trauma, testicular torsion, and tumor. Patients with testis that are rotated or elevated or 
with a history of trauma should be referred for surgical option. An STI is more likely the 
cause for men under 35 years of age than for older men. An epididymitis which is 
accompanied by urethral discharge should be treated with drugs for both gonococcal and 
chlamydial infection. 
3.5 Vaginal discharge 
An abnormal vaginal discharge in terms of quantity, color, or odor most commonly results 
from vaginal infection. Trichomonas vaginalis is the most common STI cause of vaginal 
infection, though bacterial vaginosis (BV) and yeast infections also produce vaginal 
discharge. All women presenting with vaginal discharge should be treated for 
trichomoniasis and BV, in the absence of specific diagnosis, with metronidazole, 400-500 mg 
orally twice daily for 7 days. Metronidazole is not recommended in the first trimester of 
pregnancy. Pregnant women should be treated with metronidazole, 200-250 mg orally 3 
times daily for 7 days. In rare cases, vaginal discharge may result from a mucopurulent 
cervicitis due to infection with N. gonorrhoeae or C. trachomatis. Treatment for cervical 
infection in women presenting with vaginal discharge is dependent on the local prevalence 
of these STIs. Women in high risk areas for N. gonorrhoeae or C. trachomatis with vaginal 
discharge and evidence of cervicitis should be offered treatment for these STIs in addition to 
treatment for BV and trichomoniasis. 
3.6 Lower abdominal pain 
There are multiple causes of lower abdominal pain in sexually active women in addition to 
pelvic inflammatory disease (PID) caused by STIs. Women presenting with lower 
abdominal pain and a missed or overdue period, pregnant, recent delivery, abortion, or 
miscarriage, abdominal guarding and/or tenderness, abnormal vaginal bleeding, or 
abdominal mass, should be referred for surgical or gynecological assessment. In the absence 
of these signs women with lower abdominal pain accompanied by cervical excitation 
tenderness or lower abdominal tenderness and vaginal discharge should be managed for 
PID. The etiologic agents for PID include N. gonorrhoeae, C. trachomatis, T. vaginalis, 
anaerobic and facultative bacteria, and perhaps Mycoplasma. When diagnostic capacity to 
distinguish these agents is absent the treatment regimen must be effective against all these 
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pathogens. The recommended syndromic treatment is a single dose therapy for gonorrhea, 
plus doxycyline, 100 mg orally twice daily, or tetracycline, 500 mg orally 4 times daily for 14 
days, plus metronidazole, 400-500 mg orally twice daily for 14 days. Patients who do not 
respond to therapy within three days should be referred for a more complete diagnostic 
evaluation. 
3.7 Neonatal conjunctivitis 
Infants with neonatal conjunctivitis (ophthalmia neonatorum) present with eyes that are red, 
swollen and accompanied by discharge (“sticky eyes”). Chlamydia trachomatis and N. 
gonorrhoeae are the most significant pathogens which cause ophthalmia neonatorum in 
developing countries although infections from Staphylococcus aureus, Streptococcus 
pneumoniae, Haemophilus spp., and Pseudomonas spp. occur. The oropharynx, urogenital tract, 
and rectum of neonates may also be affected in Chlamydia trachomatis or N. gonorrhoeae 
infection. Neisseria conjunctivitis develops within a few days of birth whereas C. trachomatis 
conjunctivitis develops slower, 5-14 days after birth. Neonatal conjunctivitis caused by N. 
gonorrhoeae can lead to blindness when untreated. Coverage should be provided for both of 
these STIs in settings where definitive diagnosis is not possible, especially where there is 
evidence of a maternal STI. Treatment should include a single dose therapy for gonorrhea 
and multiple dose therapy for chlamydia. For gonorrhea a single intramuscular injection of 
ceftriaxone, 50 mg/kg to a maximum of 125 mg total, should be administered. If ceftriaxone 
is unavailable, single injections of kanamycin or spectinomycin at 25 mg/kg to a maximum 
dose of 75 mg total may be used. For chlamydia treatment, erythromycin syrup, 50 mg/kg 
per day orally, in 4 divided doses for 14 days or trimethoprim, 40 mg with 
sulfamethoxazole, 200 mg orally twice daily for 14 days are recommended. Gonococcal 
ophthalmia neonatorum is preventable if a 1% silver nitrate solution or 1% tetracycline 
ointment is applied at birth as a prophylactic measure. 
4. Trichomoniasis 
Trichomonas vaginalis infects the urogenital tract of men and women, causing trichomoniasis. 
Trichomonas vaginalis is a member of the Phylum Zoomastigina, Class Parabasalia, Order 
Trichomonadida, and Family Trichomonadidae. Trichomonas  vaginalis has only one life 
stage, trophozoites, which display various shapes including pyriform, ameboid, ellipsoidal, 
ovoidal, and spherical. The organisms measure between 10 – 30 microns. The organism 
possesses four anterior flagella and a fifth flagellum located posteriorly along the 
undulating membrane. These flagella of the organism yield the characteristic quivering 
motion of T. vaginalis. 
4.1 Epidemiology 
Trichomoniasis is the most common, curable, non-viral sexually transmitted infection 
worldwide. An estimated 174 million new cases of trichomoniasis occur worldwide each 
year. The incidence of Trichomonas vaginalis infection varies in different countries 
throughout the world. Incidence in Asian countries varies from 0.7% in rural China to 15.1% 
in sex workers in Indonesia. In South America, studies report incidence ranging from 4-9%. 
In Brazil prevalence is thought to have a range of 20 up to 40%. Incidence in African 
countries ranges from 2-20%. The incidence of trichomoniasis is higher in sexually active 
women over 25 years of age than in younger women. 
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4.2 Clinical manifestations 
The actual number of new or existing cases of trichomoniasis is not known with complete 
surety because trichomoniasis is not a reportable disease and because of the significant 
number of asymptomatic cases. Trichomoniasis is usually asymptomatic in men, although 
sometimes it can cause non-gonococcal, non-chlamydial urethritis, epididymitis, and 
prostatitis. Clinical trichomoniasis in women ranges from asymptomatic carriers to flagrant 
vaginitis. Women have symptomatic disease more often than men. One third of 
asymptomatic woman will become symptomatic within 6 months of the onset of infection. 
Symptoms can include a vaginal discharge, vulvovaginal irritation and itching, painful 
urination or intercourse, foul odor, and lower abdominal pain. The presence or absence and 
severity of these symptoms determine whether the infection is classified as acute, chronic, or 
asymptomatic. 
4.3 Health sequelae 
Trichomoniasis is associated with a higher risk for other infectious diseases and adverse 
pregnancy outcomes such as preterm birth, premature rupture of placental membranes, and 
low birth weight infants. One study has also found an association between T. vaginalis 
infection in pregnancy and mental retardation in children. Trichomonas vaginalis infection is 
associated with pelvic inflammatory disease, especially PID leading to sterility. 
Trichomoniasis is significantly associated with HSV infection. Trichomonas vaginalis infection 
also increases the risk of human immunodeficiency virus (HIV) acquisition and the Centers 
for Disease Control and Prevention (CDC) estimates that as much as 20% of HIV 
transmission in the African American population in the United States may be attributable to 
T. vaginalis infection. Trichomonas vaginalis infection also increases the risk of cervical 
neoplasia and prostate cancer. Exposure to T. vaginalis results in a 2-fold increase in the risk 
of diagnosis of extraprostatic prostate cancer and a 3-fold increase in the risk of cancer that 
led to cancer-specific death. Thus, although trichomoniasis itself is a curable disease, T. 
vaginalis infection may indirectly be a life threatening disease.  
4.4 Diagnosis 
Because of the high prevalence of trichomoniasis, any woman seeking medical care for 
vaginal discharge should be tested for T. vaginalis infection. Trichomoniasis is traditionally 
diagnosed microscopically (wet mount) by observing mobile protozoa in vaginal secretions, 
cervical samples, or from urethral or prostatic swabs. However, this method has a relatively 
low sensitivity and requires immediate evaluation of a wet preparation slide for optimal 
results. The low sensitivity of this diagnostic method leads to under-diagnosis. The current 
gold standard for diagnosis of trichomoniasis is culture in Diamonds media and is widely 
used. Rapid antigen based point-of-care tests and nucleic acid based diagnostic tools are also 
available. Both of these techniques have high sensitivity and specificity. Papanicolaou (Pap) 
smear allows for direct visualization in saline prep and can be performed within 10-20 
minutes of sample collection but is not widely used. The Whiff test can be performed by 
mixing vaginal secretions with 10% potassium hydroxide (KOH) to yield a strong fishy 
odor. This test has a poor specificity due to the fact that bacterial vaginosis can yield a 
similar result. All of the above mentioned diagnostic methods are applicable for diagnosis in 
women. In men, culture testing of urethral swabs, urine, or semen and the nucleic acid 
amplification tests are more sensitive diagnostic tools.  
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4.5 Treatment 
Metronidazole, 2 g orally in a single dose or 500 mg orally twice a day for 7 days, is the 
treatment of choice for trichomoniasis. An estimated 2.5-10% of T. vaginalis infections show 
some degree of resistance to treatment; a resistance rate of 17.4% has been reported in Papua 
New Guinea. Treatment failures are higher in HIV-positive individuals. Recalcitrant cases 
may be treated with tinidazole at 2 g orally in a single dose. Consumption of alcohol should 
be avoided during treatment and for 24 hrs after completion of metronidazole therapy or 72 
hours after completion of tinidazole therapy. 
5. Chlamydia 
Chlamydia trachomatis is a small, obligate intracellular bacterium that typically infects non-
ciliated epithelial cells of mucous membranes; urethral epithelial cells in males and 
columnar epithelial cells of the endocervix in women. However in the lymphogranuloma 
venereum serovars, macrophages appear to be the principal host cell. Chlamydia is organized 
into multiple serovars that cause a diverse variety of human disease. Serotypes A, B, Ba, and 
C are the agents of classic blinding trachoma. Serotypes D thru K can cause adult inclusion 
and neonatal conjunctivitis, pneumonia, urogenital infections and Reiter’s syndrome. 
Serotypes L1, L2, and L3 infect tissues deeper to the epithelium and cause 
lymphogranuloma venereum (LGV).  
5.1 Epidemiology 
Chlamydia infection is the most common bacterial STI in the world and among STIs, only the 
prevalences of herpes and trichomoniasis are higher. Chlamydia infection is highest in 
sexually active young adults under 25 years of age. Chlamydia trachomatis causes 30-50% of 
nongonoccal urethritis in men and mucopurulent cervicitis in women. In men less than 35 
years of age Chlamydia is the principal cause of epididymitis. Although there is no lasting 
immunity and re-infection is common, women do clear the infection faster with increasing 
age. Lymphogranuloma venereum  (LGV) is an uncommon disease and relatively rare in 
developed countries. The disease is most common in sub-Saharan Africa and is also 
reported in areas of the Caribbean, Central America, and Southeast Asia and sporadically in 
developed nations. 
5.2 Clinical manifestations 
Symptoms of chlamydial infection typically appear 1-3 weeks post exposure. Asymptomatic 
infection is common among both men, approximately ~50%, and women, approximately 70-
80%. When it occurs, symptomatic infection clears spontaneously about 50% of the time. 
However, both untreated and asymptomatic infections can persist for years; as many as 10% 
remain infected after 3 years. Symptomatic men might have a urethral discharge and 
dysuria with burning and itching around the urethral opening. Epididymitis and prostatitis 
are sometimes present causing pain and swelling of the testes, fever, and rarely sterility. 
Chlamydial infection of the rectum can cause pruritis, rectal pain, discharge, or bleeding. 
Chlamydia infected women may experience cervicitis, vaginal discharge and dysuria. 
Infection and inflammation in the cervix may spread to the fallopian tubes and uterus, 
leading to pelvic inflammatory disease (PID). Chlamydia is among the most frequent 
pathogens associated with PID and up to 40% of women with untreated chlamydia develop 
PID. Some women with PID report lower abdominal pain, lower back pain, nausea, fever, 
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abnormal bleeding, and dysparenia but many women show no signs of infection. Untreated 
PID can result in chronic pelvic pain, tubal infertility in 10-20% of women, and occasionally 
potentially fatal ectopic pregnancy. Repeated infections increase the risk of adverse sequelae 
in both men and women. In rare cases persons with genital chlamydial infection can 
develop Reiter’s syndrome, a triad of reactive arthritis accompanied by conjunctivitis and 
urethritis. Chlamydial infection, even asymptomatic disease, increases the risk of adverse 
pregnancy outcomes: premature rupture of membranes, preterm delivery and low birth 
weight. Chlamydia can easily pass to neonates during childbirth causing neonatal 
conjunctivitis and afebrile pneumonia in approximately 60% of those with infected mothers. 
The high levels of Chlamydia infection worldwide mean that there is substantial neonatal 
morbidity from perinatally transmitted chlamydial infection. 
The Chlamydia serotypes which cause LGV are more virulent and more invasive than other 
chlamydial serotypes. The initial stage is a painless genital papule which heals rapidly and 
may be unrecognized. The organism then disseminates to regional lymph nodes, usually the 
inguinal nodes, where they replicate within macrophages and elicit a systemic response. 
This produces a painful inguinal lymphadenopathy, usually unilateral, by 2-6 weeks after 
the primary lesion often accompanied by fever, headache, and arthralgias. Rectal infection 
with LGV is characterized by a severe febrile proctocolitis, mimicking inflammatory bowel 
disease, with painful defecation, tenesmus, and less commonly a bloody mucopurulent 
discharge. Untreated LGV results in chronic inflammation with late fibrotic complications 
such as fistulas of the penis, urethra, and rectum, strictures, and genital lymphoedema and 
elephantiasis. 
5.3 Diagnosis 
Empirical evidence of Chlamydia infection is based on clinical presentation. The presence of 
greater than 10 polymorphonuclear leukocytes (PMNs) per 1000X field in vaginal discharge 
or 5 PMNs/field in urethral discharge is indicative of the cervicitis or urethritis 
characteristic of Chlamydia infection. There are currently no widely available point-of-care 
tests for Chlamydia infections. Most Chlamydia infections are detected through screening 
programs based on nucleic acid amplification testing (NAAT), antigen detection by ELISA, 
and DNA hybridization. Screening is useful for identifying asymptomatic infected 
individuals and in confirming symptomatic infections, but the delay in obtaining results 
means that initial diagnosis will be primarily based on clinical presentation. Traditional 
diagnostic techniques used for bacterial infections, culture and Gram stain, are of limited 
value for chlamydial infections. Chlamydia is an intracellular pathogen that requires tissue 
culture to propagate and so this approach is infrequently used even in developed countries. 
The unique cell wall structure of Chlamydia makes it very difficult to stain, although it is 
considered Gram negative. Direct fluorescent antibody staining can identify Chlamydia in 
clinical specimens but is not widely available. Where testing is available, all sexually active 
young adults under 25 years should be screened for Chlamydia. All pregnant women should 
be screened for Chlamydia as well. 
5.4 Treatment 
The recommended regimen for treatment of Chlamydia infection is azithromycin, 1 g orally 
in a single dose, or doxycycline, 100 mg orally twice daily for 7 days. Alternative 7 day 
regimens are 500 mg erythromycin base orally four times a day, 500 mg levofloxacin orally 
once daily, or 300 mg ofloxacin orally twice daily. The frequency of Chlamydia and 
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gonococcal co-infection is high in many locales and dual treatment should be considered. 
The recommended treatment for LGV is doxycycline 100 mg orally twice a day for 21 days 
or alternatively, erythromycin base, 500 mg orally four times a day for 21 days. 
Azithromycin, 1 g orally once weekly for 3 weeks, may also be effective but clinical data is 
lacking. LGV buboes may require aspiration.  
6. Gonorrhea 
Neisseria gonorrheoae is an intracellular Gram-negative aerobic diplococcus that is the 
causative agent of gonorrhea. The adjacent sides of the diplococci pairs are flattened giving 
a characteristic kidney bean shape. Gonococci initially penetrate mucosal columnar 
epithelial cells and pass thru to establish infection in the subepithelial space. Cell destruction 
mediated by gonococci and the host inflammatory response is responsible for the disease 
pathology. Gonococci frequently change their surface antigens and lasting immunity does 
not develop. Therefore, re-infection is common. 
6.1 Epidemiology 
Gonorrhea is the second most common bacterial STI in the world with 62 million cases 
annually and is most prevalent in south and Southeast Asia with 27 million cases annually, 
and sub-Saharan Africa with 17 million cases annually. Gonococcal infection is most 
common among young persons, particularly those 15-24 years old. Women have a 60-80% 
risk of acquiring gonorrhea from a single act of vaginal intercourse with an infected man; 
men have only a 20-50% chance of acquiring infection from intercourse with infected 
women. Transmission among men who have sex with men is more efficient than a man’s 
risk during heterosexual sex and gonorrhea prevalence is several fold higher in this 
demographic group. Pharyngeal and rectal gonococcal infection is also especially prevalent 
in this group. Co-infection with Chlamydia is common, occurring in up to 50% of gonococcal 
infections in some countries. 
6.2 Clinical manifestations 
Symptoms of infection in men usually appear 2-5 days after exposure with a range of 1-30 
days. Women are less likely to have symptomatic infection, up to 70% are subclinical, but 
those who develop symptoms do so within 10 days of infection. The majority of men with 
gonococcal infection develop urethritis with a white, yellow, or greenish urethral discharge, 
dysuria, and sometimes painful and swollen testes. Erythema of the meatus is sometimes 
observed. Non gonococcal urethritis is usually characterized by less purulent and less 
copious discharge with little erythema of the meatus. The endocervical canal is the primary 
site of infection in women. Females with endocervicitis and urethritis experience dysuria, a 
purulent vaginal discharge, pelvic pain, and pain and bleeding brought on by sexual 
intercourse. Symptoms of rectal infection include itching, mucopurulent discharge, 
bleeding, tenesmus, and painful bowel movements. Pharyngeal infection is characterized by 
exudative pharyngitis and cervical lymphadenopathy. Untreated gonorrhea can lead to 
severe complications in both men and women. Gonorrhea can spread from the cervix and 
vagina to the fallopian tubes and uterus leading to chronic salpingitis or pelvic 
inflammatory disease, ectopic pregnancy, and infertility from scaring of the fallopian tubes. 
Pregnant women may experience chorioamnionitis and septic abortion. In men 
epididymitis, usually accompanied by unilateral testicular pain and swelling with fever, is 
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relatively rare but can cause sterility. However a more likely cause of epididymitis in 
sexually active young men is C. trachomatis. Posterior urethritis, urethral stricture and 
prostatitis in men and Bartholin gland abscesses in women are additional complications of 
genital infection. In approximately 1- 3% of infected adults, with a higher occurrence in 
women, gonococci disseminates via the bloodstream to produce characteristic 
papulopustular lesions, and to infect joints, typically in fingers, wrists, toes, and ankles, 
causing septic arthritis. These manifestations are accompanied by fever and can range from 
mild to severe. Other less common complications of disseminated infection include a 
purulent conjunctivitis from autoinoculation, fatal septic shock, meningitis, perihepatitis, 
osteomyelitis, rapidly progressing endocarditis, especially of the aortic valve, and adult 
respiratory distress syndrome. Neonatal gonococcal infections are now an infrequent 
occurrence in developed countries but remain a serious problem in developing countries. 
Newborns infected during birth can develop conjunctivitis, known as ophthalmia 
neonatorum, which may lead to blindness. Neonates can also acquire pharyngeal or rectal 
infection and, rarely, develop gonococcal sepsis or pneumonia. 
6.3 Diagnosis 
There are currently five available tests for detection of gonorrhea; Gram stain, culture, 
nucleic acid amplification tests (NAAT), gonorrhea antigen detection tests, and nucleic acid 
hybridization tests. Clinical signs and symptoms of cervicitis or urethritis and the presence 
of Gram-negative intracellular diplococci within polymorphonuclear neutrophils from 
urethral, or less commonly, cervical discharge, are diagnostic for gonorrhea. The sensitivity 
of gram stain is very high in symptomatic men with urethritis but less so in infected women 
and in rectal infection. Stained smears are not recommended for diagnosis of pharyngeal 
gonococcal infection. Culture on specialized media can be used for urethral, cervical, 
pharyngeal, and rectal infection. This is the only testing technique that permits 
determination of gonococcal antibiotic sensitivity. In resource rich countries, diagnosis using 
very sensitive NAAT, gonorrhea antigen detection tests via immunoassay, and nucleic acid 
hybridization tests has become widespread. This has permitted screening of at risk 
populations and self referred testing in developed countries. NAAT tests are the most 
sensitive, and can be used on urine samples as well, but require hours to days to yield 
results. Rapid, point-of-care gonorrhea antigen detection tests and nucleic acid 
hybridization tests are in use, but are relatively expensive for settings in developing 
countries. Both of these tests are less sensitive than NAAT and are primarily designed for 
testing with cervical and urethral material. Some available NAAT, gonorrhea antigen 
detection tests, and nucleic acid hybridization tests can detect both N. gonorrhoeae and 
Chlamydia in the same sample and the NAAT test can be combined with Pap smears. 
6.4 Treatment 
The recommended treatment for gonococcal infections is ceftriaxone in a single 250 mg dose 
administered intramuscularly (IM). If unavailable cefixime, 400 mg orally in a single dose, 
or a single dose injectible cephalosporin plus azithromycin, 1 g orally in a single dose, or 
doxycycline, 100 mg orally twice a day for 7 days, may be used. Resistance to oral third 
generation cephalosporins has emerged recently and has been reported throughout Asia 
and in Australia and some European countries. The recent emergence in Japan of a strain, 
H041, which is extremely resistant to all cephalosporin-class antibiotics will pose a 
considerable public health challenge as this strain spreads throughout Asia and beyond. 
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Therapeutic use of sulfonamides, penicillin, erythromycin, and fluoroquinolones has been 
largely discontinued due to the development of widespread resistance to these agents. 
Azithromycin, 2 g orally, is effective but concerns over the prior ease of development of 
macrolide resistance in N. gonorrhoeae should limit its use to special circumstances. 
Gonococcal infections of the pharynx are more difficult to eliminate and are treated with 
ceftriaxone, 250 mg IM in a single dose, plus azithromycin, 1 g orally in a single dose, or 
doxycycline, 100 mg orally twice a day. Neonates born to infected mothers are given 
erythromycin ointment to the eyes to prevent blindness. Patients infected with N. 
gonorrhoeae are frequently co-infected with Chlamydia, and additional treatment for this 
infection may be appropriate, dependent on local prevalence of these STIs.  
7. Syphilis 
Treponema pallidum, a thin (0.1-0.18 µm by 6-15 µm) flagellated spirochete, is the etiologic 
agent of syphilis. Treponema spirochetes invade mucous membranes or penetrate through 
breaks in the skin. Although syphilis is typically acquired via sexual contact the disease can 
also be transmitted transplacentally and by exposure to blood or lesion exudates from 
infected persons in the primary and secondary stages of disease. 
7.1 Epidemiology 
Prior to the antibiotic era, syphilis was a very prevalent disease, particularly in large urban 
areas. Since then, the incidence has been steadily declining but there are still 12 million new 
cases each year around the world. Unlike many other STIs, the incidence of syphilis is 
higher in older individuals and is highest in men aged 30-45. Globally, congenital syphilis is 
a significant problem and it is estimated that neonatal mortality from syphilis exceeds that 
of neonatal tetanus, neonatal HIV infection, and mortality from malaria in pregnancy. There 
is no lasting immunity to syphilis and patients can be re-infected. 
7.2 Clinical manifestations 
Syphilis presents a wide spectrum of clinical manifestations as it progresses through the 
different stages of the disease: primary, secondary, latency, and tertiary. Syphilis, 
particularly the secondary stage, mimics many other infections and has been given the 
moniker, the “great imitator”. The primary stage of syphilis is usually characterized by the 
appearance of a single sore (chancre) at the site of syphilis entry, although multiple lesions 
can be present. The chancre appears 10-90 days after infection, approximately 2-3 weeks on 
average. The chancre is typically a firm, round, and painless ulcer, 1-2 cm in size, which is 
highly infectious and will spontaneously resolve in 1-6 weeks. Chancres can also be present 
at non-genital sites, the anus, mouth, or perineum. Regional lymphadenopathy that is 
rubbery, painless, and bilateral is usually present.  
Without treatment the systemic skin rash and mucocutaneous lesions of secondary syphilis 
appear 4-6 weeks after the primary lesion in approximately 25% of patients following 
dissemination of the disease throughout the body. Occasionally the symptoms of secondary 
syphilis will occur prior to resolution of the initial chancre. The red macropapular rash is 
symmetrical, non-pruritic, and present throughout the body including the palms of hands 
and soles of feet and may lead to hair loss. White, patchy, raised lesions on 
mucocutaneous surfaces, known as condylomata latum may also be present. The rash and 
lesions are accompanied by fever, malaise, and generalized lymphadenopathy. Rare 
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manifestations of secondary syphilis include hepatitis, glomerulonephritis, and keratitis. 
Neurosyphilis can occur at any stage of syphilis but is classically associated with tertiary 
syphilis. Clinical manifestations of early neurosyphilis include acute syphilitic meningitis 
that typically involves cranial nerves III, VI, VII and VIII; or meningovascular syphilis, a 
stroke-like syndrome with seizures. Secondary syphilis is usually the fist clinical 
presentation in persons practicing receptive vaginal or anal intercourse as the primary 
lesions are often not noticed.  
Whereas some secondary syphilis can spontaneously resolve, if untreated, approximately 
two thirds of secondary syphilis cases enter into a prolonged period of latency where 
symptoms of infection are absent. Relapses of secondary symptoms may occur in up to 25% 
of untreated patients, usually within the first year of infection. The latent stage can last for 
up to 25-30 years but if untreated, about one third of latent infections will progress to 
tertiary syphilis. Tertiary syphilis is rare in developed countries due to early diagnosis and 
treatment of syphilis. Tertiary syphilis is characterized by destructive lesions known as 
gummas, neurologic involvement, and cardiovascular lesions. Gummas, are highly 
destructive granulomas, usually in the skin, bone and mucosal areas but are sometimes 
found in other tissues such as genitals, lung, stomach, liver, spleen, spinal cord, breast, 
brain, and heart. Onset is 10-15 years after infection. Cardiovascular syphilis generally 
appears about 20-30 years after infection when lesions in the cardiac vasculature produce 
ascending aortic aneurysm, aortic insufficiency, or coronary ostial stenosis. In tertiary 
neurosyphilis focal endoarteritis in the blood vessels of the brain and spinal cord provokes 
signs and symptoms, usually decades after infection, which may resemble other neurologic 
diseases. Clinical manifestations typically include general paresis and tabes dorsalis. The 
presence of oral syphilitic lesions is common, particularly in primary and secondary 
syphilis, and in regions with a high prevalence of syphilis other health care workers, such as 
dentists, need to be aware of this risk. 
7.3 Congenital syphilis 
Worldwide each year over 2 million pregnant women, 1.5% of all pregnancies, test positive 
for syphilis. Treponema spirochetes can cross the placenta to infect the fetus resulting in 
severe adverse pregnancy outcomes. Untreated maternal syphilis will result in stillbirth, 
premature birth, neonatal death, or congenital infection in up to 80% of pregnancies in 
developing countries. An estimated 25% of all stillbirths and 11% of neonatal deaths in 
developing countries are due to fetal syphilis exposure. Symptoms of early congenital 
syphilis in children less than 2 year old include cutaneous and mucocutaneous lesions, 
macropapular rash, hepatosplenomegaly, lymphadenopathy, bone alterations from osteitis 
and osteochondritis, meningitis, pneumonia, and testicular masses. Hematologic 
abnormalities such as thrombocytopenia and anemia may occur. Early congenital syphilis is 
more common than late congenital syphilis. Late congenital syphilis in children >2 year old 
is characterized by Hutchinson’s triad, Saddle nose, and bone deformations such as Saber 
shins. Hutchinson’s triad includes tooth deformations where the crown of the incisors is 
wider in the cervical portion than at the incisor edge and a crescent-shaped notch is present 
at the incisor edge, interstitial keratitis which can lead to blindness, and eighth nerve 
deafness. Saddle nose refers to collapse of the bridge and resulting dorsal depression due to 
erosion of septal support, giving a saddled appearance. Saber shin is a malformation of the 
tibia with sharp anterior bowing. Interstitial keratitis is the most common manifestation of 
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late congenital syphilis. These adverse pregnancy outcomes can be prevented by syphilis 
screening to identify and treat maternal infections prior to 24 weeks gestation. 
7.4 Diagnosis 
Initial diagnosis of syphilis is typically based on clinical presentation. Treponema spirochetes 
are Gram negative but they cannot be visualized using conventional light microscopy. 
Darkfield microscopy and direct fluorescent antibody test of spirochetes from lesion 
exudates and tissue provide definitive diagnosis of early syphilis. These tests however are 
not utilized in most settings. Presumptive diagnosis of syphilis relies on two types of testing 
for antibody in blood serum or cerebrospinal fluid. The Venereal Disease Research 
Laboratory (VDRL) and Rapid Plasma Reagin (RPR), Toluidine Red Unheated Serum 
(TRUST), and Unheated Serum Reagin (USR) tests utilize a non-treponemal antigen. The 
VDRL and RPR tests are the most widely used of these. VDRL and PRP testing is most 
sensitive in the middle stages of the disease, early syphilis and late stage disease may be 
missed. Detectable antibody titers are not attained until 1-4 weeks after appearance of the 
chancre and titers often decline to undetectable levels in latency. Non-treponemal tests are 
nonspecific and can give false-positive results and occasionally false negative results under 
conditions of antibody excess which can occur during secondary syphilis. Positive results 
are confirmed with a test utilizing treponemal antigens, such as the fluorescent treponemal 
antibody absorbed (FTA-ABS) test, treponemal enzyme immunoassay (EIA), 
microhemagglutination assay for T. pallidum antibodies (TPHA), and direct fluorescent 
antibody-T. pallidum test (DFA-TP). These tests are more sensitive than non-treponemal tests 
in detecting primary and tertiary syphilis. Non-treponemal test antibody titers usually 
correlate with disease activity and become non-reactive with time after treatment. 
Treponemal test antibody titers do not correlate disease activity and most (75-85%) will 
remain reactive for the rest of their lives. Commercially available point-of care tests for 
syphilis have been introduced recently although these are too expensive for most situations 
in the developing world.  
7.5 Treatment 
Benzathine penicillin G, 2.4 million units by intramuscular injection (IM) in a single dose for 
adults or 50,000 units/kg IM for children, is the preferred treatment for primary, secondary, 
and early latent stage syphilis. Alternatively, procaine penicillin at 1.2 million units IM daily 
for 10 days is used. Penicillin allergic non-pregnant patients may be treated with 
doxycycline, 100 mg orally twice daily for 2 weeks or tetracycline, 500 mg orally four times 
daily for 2 weeks. Penicillin allergic pregnant patients may receive erythromycin, 500 mg 
orally, 4 times daily for 14 days. Late latent stage syphilis and tertiary syphilis is treated 
with three doses benzathine penicillin G at 1 week intervals, 2.4 million units IM each dose 
for adults and 50,000 units/kg for children. Alternatively, procaine penicillin at 1.2 million 
units IM daily for 20 days is used. Penicillin allergic non-pregnant patients with late latent 
stage or tertiary syphilis may be treated with doxycycline, 100 mg orally twice daily for 4 
weeks or tetracycline, 500 mg orally four times daily for 4 weeks. Penicillin allergic pregnant 
patients may receive erythromycin, 500 mg orally 4 times daily for 4 weeks. Neurosyphilis is 
treated with intravenous aqueous crystalline penicillin G, 3-4 million units every 4 hours 
(18-24 million units per day) for 10-14 days, or with daily IM injections of procaine 
penicillin, plus 500 mg probenecid orally 4 times daily, both for 10-14 days. Penicillin 
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allergic non-pregnant patients with neurosyphilis are treated with doxycycline, 200 mg 
orally twice daily for 4 weeks or tetracycline, 500 mg orally four times daily for 4 weeks. 
Non-penicillin allergic pregnant women diagnosed with syphilis are treated with penicillin 
according to the stage of infection. Early congenital syphilis should be treated with 
intravenous aqueous crystalline penicillin G at 50,000 units/kg/dose every 12 hours for the 
first 7 days and every 8 hours for the next 3 days. Alternatively early congenital syphilis is 
treated with IM injections of procaine penicillin at 50,000 units/kg daily for 10 days. Late 
congenital syphilis is treated with intravenous or intramuscular aqueous crystalline 
penicillin G at 50,000 units/kg/dose every 4-6 hours for 10-14 days. For penicillin allergic 
children, after the first month of life, administer erythromycin, 7.5-12.5 mg/kg orally, 4 
times daily for 4 weeks. 
8. Chancroid 
Haemophilus ducreyi, a fastidious Gram-negative facultative anaerobic coccobacillus, is the 
causative agent of chancroid. Chancroid is transmitted by vaginal, anal, or oral sex with an 
infected individual. The organism enters thru breaks in the epithelium and resides primarily 
in the extracellular spaces. Haemophilus ducreyi can resist phagocytosis and untreated lesions 
may take months to heal. 
8.1 Epidemiology 
Globally, chancroid is the most common cause of genital ulcer disease in regions where the 
disease is endemic. WHO estimates the annual global incidence to be about 6 million cases. 
Chancroid occurs in parts of Africa, south-east Asia and the Caribbean where it accounts for 
23-56% of genital ulcer disease. Chancroid is more common in men than women and more 
common in areas where HIV prevalence is high (>8%). The incidence of chancroid is much 
lower in developed countries and sporadic outbreaks there are associated with travel, 
prostitution, and drug use. Chancroid, as are all genital ulcer producing STIs, is a risk factor 
for HIV transmission. 
8.2 Clinical manifestations 
After an incubation period of several days to two weeks, a tender erythematous papule 
develops at the site of inoculation which progresses to a pustular stage. The pustle ruptures 
within 2-3 days to form a painful genital ulcer with soft edges. Chancroid ulcerative lesions 
vary from 3-50 mm across but are typically 10-20 mm. Chancroid ulcers can be irregular, 
round, or oval in shape, are sharply circumscribed with an undermined edge, and contain a 
grey or yellow purulent exudate. Lesions will have a surrounding cutaneous erythema. One 
half of men have only a single ulcer and lesions typically appear on the penis: penile shaft, 
coronal sulcus, prepuce, urethral meatus, and glans. In women infection is often subclinical. 
Women have multiple ulcers more frequently than men that may merge to form large 
ulcers. Ulcers in women occur on the fourchette, labia majora, labia minora, cervix, perianal 
region, and inner thighs. “Kissing ulcers” may develop on the skin surfaces apposing the 
initial ulcer. Women may also experience dysuria and dyspareunia. Rectal sores in men or 
women may bleed or cause pain during defecation. Buboes, swelling of the inguinal lymph 
nodes, occur in one third to one half of infected individuals 1-2 weeks after the ulcers form 
and these may rupture, producing draining abscesses. The development of buboes is a more 
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common occurrence in men than women. Buboes are painful, tender, and fluctuant with 
underlying erythema, and are typically unilateral. Supperative adenopathy is almost 
pathognomonic for chancroid. The skin over the bubo does not become thickened and 
edematous or show furrows as in the adenopathy of LGV. Chancroid can also spread via 
self inoculation to other anatomical sites. Chancroid in HIV-infected patients may produce a 
larger number of ulcers, atypical ulcers, extra-genital lesions, and longer lasting ulcers even 
with treatment. 
8.3 Diagnosis 
Definitive diagnosis of chancroid requires cultivation of H. ducreyi on special culture media, 
which is not routinely carried in most laboratories. Culture on two media is recommended as 
not all H. ducreyi strains can be cultured using one medium. Culture also requires a humid 
environment, 5% CO2, and incubation at 33-35 oC. Swabs for culture are collected from the 
undermined edge of the ulcer and the fastidious nature of H. ducreyi necessitates use of 
transport media if the organisms are not cultured within a few hours. Presumptive diagnosis 
by microscopy is possible if the organism load in ulcers is high and Gram-negative 
coccobacillus arranged in chains, paired chains or aggregates (“school of fish” appearance) are 
visualized. However the value of microscopy for diagnosis is limited by low sensitivity and 
specificity of this technique. Aspirates from buboes are less likely to yield positive results on 
microscopy or culture. In many cases chancroid is diagnosed clinically and treated without a 
definitive diagnosis. The combination of painful genital ulcer and suppurative inguinal 
lymphadenopathy is also supportive of a diagnosis of chancroid. Nucleic acid amplification 
tests for diagnosis have been developed but are not widely available. 
8.4 Treatment 
Azithromycin (1 g orally) or ceftriaxone (250 mg IM) offer the advantage of single-dose 
therapy. Alternatively ciprofloxacin (500 mg orally twice daily for 3 days) or erythromycin 
base (500 mg orally three times a day for 7 days) may be used. For reasons of cost, 
erythromycin is usually used for treatment in developing countries. Isolates with 
intermediate resistance to ciprofloxacin or erythromycin have been reported but data are 
rather limited on the current status of H. ducreyi drug resistance. Ulcerative lesions should 
be kept clean to avoid the chance of secondary infections. Fluctuant lymph nodes can be 
aspirated through healthy skin. Incision and drainage or excision of nodes may delay 
healing. Uncircumcised men and HIV-positive patients may not respond as well to 
treatment. Large ulcers may require weeks to resolve after treatment and patients should be 
followed until there is clear evidence of improvement or cure.  
9. Human papilloma virus 
Human papillomavirus (HPV) is a member of the papillomavirus family of viruses that 
infect only humans. HPVs can be divided into two general groups based on their preferred 
infection site: cutaneous and mucosal. Genital HPV, a member of the mucosal HPVs, is 
transmitted through sexual contact and infects the anogenital regions. There are more than 
40 types of HPV that infect the genital area. Non-oncogenic or low risk HPV types are the 
causative agents of genital warts and recurrent respiratory papillomatosis. Oncogenic or 
high risk HPV types are the cause of cervical cancers and are associated with other 
anogenital cancers in men and women. 
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9.1 Epidemiology 
Genital human papillomavirus is considered to be one of the most prevalent STIs in the 
world. It is estimated that more than 50% of sexually active individuals become infected at 
least once in their life. WHO estimates that 14.3% of women in developing regions and 
10.3% of women in developed regions with normal cervical cytology are infected with HPV. 
Incidence of HPV in women increases significantly with severity of abnormal cervical 
cytology. Prevalence of HPV reaches to greater than 70% in women with cervical cancer. 
9.2 Clinical manifestations 
Asymptomatic genital HPV infection is common and usually self-limited. Seventy percent of 
infections are gone in 1 year, and 90% in 2 years. The most common symptom of genital 
HPV infection is genital warts, also known as condylomata acuminata. Genital warts appear 
as a small white bump or groups of bumps in the genital area. Genital warts are usually flat, 
papular, or pedunculated growths. However, they can be small or large, raised or flat. 
Genital warts are usually themselves asymptomatic, but can sometimes be painful and 
pruritic, depending on the size and anatomic location. Growths commonly occur around the 
introitus in women, under the foreskin of the uncircumcised penis, and on the shaft of the 
circumcised penis. Genital warts can also be found in or on the cervix, vagina, urethra, 
perineum, perianal skin, and scrotum. Intra-anal warts are most often observed in 
individuals who have had receptive anal intercourse, but may be present in men or women 
with no history of anal sexual contact. 
9.3 Health sequelae 
The correlation between persistent HPV infection and cervical cancer has been well 
established. Cervical cancer is the 2nd most common cancer among women, worldwide. 
Eighty-six percent of these cases occur in developing countries, making up 13% of the world 
female population. There is now increasing evidence linking HPV to anogenital cancers 
other than cervical cancer. These include anal, vulvar, vaginal, penile, and head and neck 
cancers. Anal cancer occurs rarely with about 99,000 cases in 2002, sixty percent of cases 
occurring in women and 40% in men. This type of cancer is more prevalent in populations of 
men who have sex with men and HIV-positive populations. Vulvar cancers make up about 
3% of the gynecological cancers, with 40% of them occurring in developing countries. The 
majority of these cases occurring in the developed world suggest that HPV screening may 
not be an effective preventative method. Vaginal cancers make up 2% of gynecological 
cancers, with a majority of vaginal cancers (68%) occurring in developing countries. Penile 
cancer represents 0.5% of cancers in men. In western countries, incidence if penile cancer in 
men is less than 1 per 100,000, however, this rate increases in Latin America, India, and 
Thailand. Two-thirds of oral cancers occur in developing countries and about 15-20% of oral 
cancers are associated with HPV infection. Growing evidence suggests that HPV-related 
oral pharyngeal cancers are associated with the practice of oral sex. 
9.4 Diagnosis 
The presence of genital warts is a straight forward method for diagnosis of HPV. However, 
in the case of asymptomatic infections, there is no general diagnostic test used to screen 
normal patients for HPV. The Papanicolaou test (Pap smear or Pap test) is a cytological 
examination of cervical tissue sample that is used to screen for cervical cancer or 
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precancerous lesions. The Pap smear is more commonly used in developed countries. 
Abnormal results for a Pap smear usually result in screening of the tissue sample for the 
presence of HPV DNA. HPV DNA testing has been shown to have a higher sensitivity than 
cytology and a high negative predictive value for detecting cervical precancerous lesions. 
Other diagnostic strategies include visual inspection with acetic acid (VIA), self-vaginal 
sampling, and liquid based cytology (LBC). VIA has shown sensitivity similar to that seen 
with cytology, but has a lower specificity, which could lead to over treatment. However, its 
use has shown a decrease in the incidence of and mortality from cervical cancer, and may 
therefore be a useful method in resource poor areas. Developing countries have attempted 
to implement HPV screening programs with variable success. Successful implementation of 
these programs in some countries such as Taiwan, Japan, Singapore, and developed African 
countries has caused a decline in incidence and mortality of cervical cancer. In the 
remainder of the developing world either no screening programs currently exist or 
screening has had little success due to poor infrastructure and competing health priorities in 
these countries. 
9.5 Treatment 
Treatment is not recommended for subclinical genital HPV because these infections 
typically clear spontaneously. However, there are treatments for the diseases that are caused 
by HPV infection. Genital warts can resolve themselves or be removed by patient-applied or 
provider-administered therapy. Patient-applied therapy recommended by the CDC consists 
of podofilox 0.5% solution or gel, imiquimod 5% cream, or sinecatechins 15% ointment. 
Provider-administered therapy is cryotherapy with liquid nitrogen or cryoprobe 
applications ever 1-2 weeks, 10-25% podophyllin resin in a compound tincture of benzoin, 
80-90% trichloroacetic acid (TCA) or bichloroacetic acid (BCA), or surgical removal by 
tangential scissor excision, tangential shave excision curettage, or electrosurgery. No 
evidence suggests that one treatment regimen is better than the other. Treatment against 
cervical lesions includes removal of precancerous lesions using cryotherapy and continuous 
preventative screening of cervical tissue. 
A preventive strategy based on the development of vaccines against HPV is now widely 
available across the globe. A quadrivalent vaccine, Gardasil (Merck Co.) protects against 2 
types of HPV that cause 75% of cervical cancer (HPV 16 &18) and the 2 types of HPV that 
cause 90% of genital warts (HPV 6 & 11). Gardasil can be used for both males and females 
ages 9-26. This vaccine is given in a series of 3 0.5 mL intramuscular injections at 0, 2, and 6 
months. A bivalent vaccine, Cervarix (GlaxoSmithKline), protects against HPV 16 & 18 and 
is only approved for women ages 10-25. This vaccine is given in a series of 3 intramuscular 
0.5 mL doses at 0, 1, and 6 months. Many countries have developed their own individual 
vaccine schedules. Both vaccines have been shown to be highly immunogenic and effective 
in prevention of incidence and persistent HPV infections that could lead to the development 
of precancerous lesions. It is recommended that vaccination begin at ages at which 
individuals have not yet become sexually active. 
10. Herpes 
Genital herpes is caused by herpes simplex viruses type 1 (HSV-1) or type 2 (HSV-2) with 
HSV-2 the primary genital STI. HSV-1 is acquired orally, usually in childhood, and typically 
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causes cold sores and sometimes keratitis. HSV-1 can also cause genital infection but 
recurrent episodes during infection with HSV-1 are much less frequent. HSV-1 and HSV-2 
are typically transmitted during sexual contact by virus shed from herpes sores but virus 
can also be released intermittently between outbreaks from skin without apparent sores. 
Herpes virus enters through mucous membranes or breaks in the skin and replicates locally 
in mucosal epithelial cells. Between outbreaks the herpes virus ascends peripheral sensory 
neurons to the dorsal root ganglia and becomes latent.  
10.1 Epidemiology 
Herpes is the most common STI in the world and HSV-2 infection is the main cause of 
genital ulcers in developing countries. An estimated one sixth to one third of the world’s 
population has genital herpes caused by HSV-2. HSV-2 prevalence is greater than 60% in 
sub-Saharan Africa and East Asia and between 25-40% in Latin America, Eastern Europe, 
South Asia, and South-east Asia. HSV-2 prevalence rates are less than 20% in North America 
and Western Europe and below 10% in North Africa, the Middle East, Japan, Australia and 
New Zealand. Most herpes infections are asymptomatic and herpes is usually spread by 
people who are unaware they have the disease. Symptomatic genital herpes infection is 
approximately twice as common in women as in men. Transmission from an infected male 
to a female partner is more likely than transmission from infected female to a male partner 
during vaginal intercourse. Rates of herpes infection are also higher in men who have sex 
with men and in HIV-positive individuals. Herpes seroprevalence rates are as high as 80% 
among HIV-positive populations in North America, Europe and Africa.  
10.2 Clinical manifestations 
Most individuals have no or only minimal symptoms from herpes infection and do not 
realize they are infected. Herpes appears 2-7 days after infection as small, pruritic and 
painful, usually multiple, grouped vesicles (blisters) with a red base on or around the 
genitals and rectum or on the buttocks or thighs. The vesicles will ulcerate to leave shallow 
lesions that heal in 2-4 weeks. During the initial episode additional groups of sores may 
appear. Fever, malaise, and bilateral inguinal lymphadenopathy that is firm and tender may 
also be present. Infection in women usually involves the vulva, vagina, and cervix. In men 
lesions usually appear on the glans penis, prepuce, or penile shaft. After resolution of the 
primary infection herpes enters a latent state. However, outbreaks will re-occur from weeks 
to months after the initial infection, particularly during periods of stress or illness, and 
typically 4 or 5 outbreaks occur within the first year. About one half of patients experience 
prodromal symptoms of tingling or pain at the eruption site 1-2 days prior to the 
appearance of lesions. Although herpes infection persists indefinitely outbreaks diminish in 
number and severity with time. The duration and intensity of outbreaks are usually more 
severe in persons with suppressed immune systems. Persons with immune deficiencies such 
as HIV-infected persons may have persistent, extensive, and severe mucocutaneous lesions 
involving large areas of perianal, scrotal, or penile skin. Complications of herpes infection 
include an aseptic meningitis in as many as 10% with primary infection, transverse myelitis, 
and perinatal transmission. Pregnant women experiencing primary genital herpes during 
birth can transmit a potentially fatal herpes infection to their infant and a caesarean delivery 
may be appropriate in these cases. The risk of transmission during birth is very low in 
women with recurrent disease. Infected neonates can experience disseminated disease with 
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organ failure, severe neurologic damage, ocular involvement, cutaneous and 
mucocutaneous sores, and even death. 
10.3 Diagnosis 
There are four types of testing employed in herpes diagnosis, DNA testing, antibody testing, 
antigen testing, and herpes culture. Nucleic acid amplification tests are very sensitive and 
can detect herpes DNA in samples from herpetic sores even when virus is in low copy 
number, such as in older lesions or in cerebrospinal fluid samples. It is the method of choice 
to detect HSV meningitis, encephalitis, and keratitis. HSV antibody tests are available to 
measure both IgM antibody, which can detect primary herpes infection after first several 
days of infection, and IgG antibody, which indicates prior HSV infection. The presence of 
HSV-2 antibody indicates anogenital infection but the presence of HSV-1 antibody does not 
distinguish genital infection from oral infection. Rapid antibody tests are available that 
detect antibodies to HSV-2 in blood from a finger stick within 10-15 minutes. The relatively 
quick turnaround and ease of this antibody tests makes it ideal for herpes screening for 
persons with undiagnosed disease as well as disease diagnosis. Fluorescently labeled 
antibody is used in antigen tests to detect markers expressed on herpes infected cells. 
Herpes culture is very specific but prone to false negative results, especially for recurrent 
infection, and requires several days to a week for results. Material from the base of the ulcer 
in fresh primary lesions is best for any herpes diagnosis as viral shedding decreases as 
lesions age and heal and in subsequent outbreaks. However, the requirement for tissue 
culture of host cells to grow herpes limits the utilization of this technique. Herpes can also 
be diagnosed by visual examination for the characteristic vesicles and sores although signs 
and symptoms of herpes can vary, making diagnosis problematic in some patients. 
10.4 Treatment 
There is no effective treatment for genital herpes but antiviral medications can lessen the 
duration and severity of outbreaks. Antiviral prophylaxis also reduces the chances of 
transmission from infected individuals to uninfected partners. Clinical episodes can be 
treated by acyclovir in a 7 day regimen for the initial episode or a 5 day regimen for 
subsequent episodes at 200 mg orally 5 times daily or 400 mg orally 3 times daily. Ideally 
treatment should begin within one day of the appearance of the herpes vesicles. Suppressive 
therapy uses acyclovir, 400 mg orally twice daily, continuously. Alternatively the acyclovir 
analogues valaciclovir and famciclovir can be used for treatment and prophylaxis although 
the dosages and regimens may vary. The acyclic nucleoside drugs are effective and well 
tolerated in most patients. Immunosuppressed individuals such as HIV-positive patients 
may respond poorly to treatment and require larger doses and longer treatment schedules 
or even parenteral drug administration.  
11. Granuloma inguinale (Donovanosis) 
Calymmatobacterium granulomatis is an intracellular Gram-negative facultative aerobic 
coccobacillus that is the causative agent of granuloma inguinale. Other designations for this 
disease include granuloma venereum and donovanosis, named for the discoverer of the 
infectious agent. A close phylogenetic relationship with Klebsiella spp. has led some to call 
for a reclassification of Calymmatobacterium into the genus Klebsiella. Some C. granulomatis 
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strains are capsulated. Calymmatobacterium granulomatis resides in the cytoplasm of 
mononuclear phagocytes or histiocytes in tissue. 
11.1 Epidemiology 
The incidence of granuloma inguinale has decreased in recent years but it still endemic in 
certain tropical and subtropical regions; south-east India, Indonesia, Papua New Guinea, 
South Africa, Guyana, Peru, Argentina, Brazil, and among aborigines of Central Australia. It 
is only occasionally reported in developed countries. Most infections occur in sexually active 
people 20-40 years of age and men are more than twice as likely to have disease. Granuloma 
inguinale is spread primarily thru vaginal or anal intercourse, infection via oral sex is rare. 
Non-sexual transmission via contact with infected material from lesions or by fecal 
contamination is possible. 
11.2 Clinical manifestations 
The infection begins approximately 10-50 days after exposure with the appearance of small, 
relatively painless, erythematous pustules or subcutaneous nodules. These will ulcerate to 
produce shallow and sharply demarcated lesions. Four types of lesions are described: 
ulcerogranulomatous ulcers, the most common, oozing lesions with a beefy red friable base 
that bleeds when touched, hypertropic ulcers with a raised irregular edge, sometimes 
completely dry, deep necrotic ulcers with an offensive smell from decaying tissue, and 
sclerotic ulcers with fibrous and scar tissue. In early stages the ulcers resemble chancroid, in 
later stages granuloma inguinale may resemble LGV. The lesions slowly expand destroying 
adjacent tissue. Anatomical areas most commonly infected in men include the sulcus, 
subprepucial region, and the anus. Women are most affected in the labia minor, fourchette, 
and occasionally in the cervix and upper genital tract. Extra-genital lesions occur in a 
minority of patients, these are secondary to the genital lesions. Oral lesions are the most 
frequent, loss of teeth indicates oral bone involvement, but lesions are possible on any 
surface. Very rarely disseminated donovanosis may occur, spreading to cause lesions in the 
liver, other organs, and bone, particularly tibia. Disseminated disease may be fatal as a 
diagnosis of donovanosis is rarely considered. Inguinal lymphadenopathy is generally 
absent. Untreated disease results in the destruction of genital tissue with scarring. 
11.3 Diagnosis 
Granuloma inguinale is diagnosed by clinical signs, particularly the presence of persistent 
spreading lesions, and the demonstration of intracellular Donovan bodies in the cytoplasm 
of mononuclear phagocytes or histiocytes present in scrapings or punch biopsies stained 
with Giemsa, silver, or Wright’s stain. Specimens from just below the surface of the ulcer are 
most likely to yield positive results. Culture is difficult to perform as it requires growth of 
host cells and is not readily available. 
11.4 Treatment 
WHO guidelines recommend azithromycin, 1 g orally followed by 5500 mg daily or 
doxycycline, 100 mg orally twice daily but do not state the duration of therapy. Typically 
therapy is given for 3-6 weeks or until lesions are healed. Alternative regimens are 
erythromycin, 500 mg orally 4 times daily or tetracycline, 500 mg orally 4 times daily or 
trimethoprim 80 mg/sulfamethoxazole 400 mg, 2 tablets orally twice daily for a minimum 
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of 14 days. WHO recommends the addition of a parenteral aminoglycoside, such as 
gentamicin, for the therapy of HIV-positive patients. Treatment should be continued until 
complete healing is achieved. The intracellular residence of C. granulomatis makes it 
somewhat resistant to treatment.  
12. STIs among travelers and immigrants from the tropics 
Travel is known to be a major factor in the spread of STIs around the world, particularly in 
developing countries where STIs are endemic and very high rates are encountered in 
commercial sex workers. The rapid spread of antibiotic resistance around the world for a 
number of STIs and the spread of HIV infection are cases in point. It is difficult to assess the 
risk of acquiring STIs during travel in which sexual acts occur. Poverty and lack of legal 
enforcement certainly facilitate access to sexually compliant individuals in the developing 
world. In addition, risk-taking behavior increases when on vacation and often vacations 
involve higher risk activities than the traveler typically encounters at home. Studies have 
shown that engaging in sexual activity is the specific reason for travel, i.e. ‘sex vacations’, in 
some travelers. Reports of lower condom rate usage and higher rates of engagement in 
anonymous sex by travelers support a conclusion of increased risk. Travel clinics and 
physicians advising overseas travelers should counsel travelers about the risks and proper 
prophylactic regimens available. Travelers should also be strongly encouraged to be tested 
for STIs upon return if they have engaged in sexual activity. There are high rates of 
asymptomatic infection for many STIs and long incubation periods can also occur before 
there is an onset of symptoms. Immigrants and refugees pose a problem to the health care 
system in developed countries as well. STIs uncommon in the developed world such as 
chancroid, LGV, and donovanosis present a diagnostic challenge to the physician unfamiliar 
with these diseases. Incorrect diagnosis and subsequent incorrect treatment can delay 
resolution of the disease and increase the risk to the patient and sex partners, even 
permitting local mini-epidemics of new STIs. Health care providers should be aware of 
uncommon STIs present in their patient’s country of origin when evaluating symptoms of 
genital infection in this population. 
13. Prevention and control 
Prompt diagnosis and treatment of infected individuals and public education of sexually 
active populations on proper prevention and prophylactic measures for STIs are the 
foundation of STI prevention and control. To be successful this approach should be 
supplemented with screening programs to identify individuals with subclinical infections as 
many, if not most, STIs are transmitted by individuals who do not know they are infected. 
However, the lack of adequate diagnostic capacity in most tropical settings severely 
compromises diagnosis and screening for STIs. This is the biggest barrier to addressing the 
STI epidemic in the developing world. Provision of a minimal diagnostic capacity, both 
equipment and trained individuals, at the initial point of contact with STI patients would 
yield enormous benefits. The development of affordable point-of care tests for STIs would 
also significantly advance efforts for controlling STIs in these countries. Public health 
education initiatives for STIs should encourage safe sex behavior and emphasize the 
advantages of prompt access to healthcare for suspected infections. Education is key to 
changing sexual behavior in high risk groups, especially adolescents and young adults who 
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are disproportionately afflicted by STIs. Some health care advisors have advocated a policy 
of treating all sexually active adolescents and adults in a village or locale as a means to 
controlling STIs, an approach similar to mass treatment with anti-helminthics utilized to 
control the endemic of intestinal worm disease. This approach may be the single most cost 
effective mechanism for managing the STI epidemic in developing countries and should be 
given careful consideration. Although perhaps not applicable for all STIs, certainly for 
highly prevalent STIs with drugs that are inexpensive, safe, efficacious, and well tolerated, 
such as metronidazole for treating trichomoniasis, this approach has much merit. 
On an individual basis the only truly reliable protection is abstinence from sexual activity. 
People in long term monogamous relationships also have greatly reduced risk of STIs and 
HIV. Vaccines are available for the prevention of HPV infection and potential HIV vaccines 
are in clinical trials. Protective measures for sexually active individuals include reducing the 
number of sexual partners and the use of latex condoms and other barriers during sexual 
activity. Consistent and proper use of condoms has been shown to reduce the transmission 
of STIs and HIV. Male circumcision has also been shown to be significantly protective 
against transmission of HIV and STIs. STI treatment should include sexual partners of the 
index case whenever possible to prevent re-infection and to reduce disease transmission. 
Due to compliance issues and difficulties in following patients in many locales, directly 
observed single dose therapies are preferred for the treatment of STIs.  
14. The future: Vaccines for STIs 
Vaccination offers the ultimate tool for control of STIs; prevention before exposure. Safe and 
efficacious vaccines could eliminate the vast majority of STI-associated morbidity and 
mortality. Unfortunately this goal has only been attained relative to HPV infection (section 
9.5) and prospects for additional STI vaccines in the immediate future are remote. In part, 
this is because the precise correlates of protective immunity have not been well-defined for 
these STIs. However, some progress has been made in the development of vaccines for 
genital herpes and Chlamydia infection. Three types of herpes vaccines have shown efficacy 
in animal models: (i) HSV-2 subunit vaccines combined with adjuvant; (ii) gene delivery 
vehicles, such as vaccinia virus, Listeria or Salmonella typhimurium, expressing HSV-2 
proteins; and (iii) attenuated (replication-defective) HSV-2 viruses. Subunit vaccines based 
on herpes glycoproteins gD and gB have failed in two human clinical trials. Live attenuated 
viruses have not been tested in humans to date although they have shown the most promise 
in animal models. Recent progress in identification of T-cell epitopes mediating 
asymptomatic versus symptomatic disease manifestation should enhance future 
development of a herpes vaccine. Chlamydia candidate vaccines containing Chlamydia major 
outer membrane protein (MOMP) with HPV major capsid membrane protein L1, 
recombinant MOMP with cholera toxin, co-expressed Chlamydia Porin B and polymorphic 
membrane protein-D proteins in a Vibrio cholerae ghost delivery system, MOMP-based DNA 
vaccines, and live attenuated Chlamydia organisms have each shown efficacy in animal 
models but none have advanced to human trials.  
Although the lack of progression to disease in some individuals infected with gonorrhea, 
syphilis, chancroid, and granuloma inguinale and the ability of immune responses to 
contain and clear infections in others in the absence of treatment indicates the theoretical 
feasibility of vaccination, progress on the development of a vaccine for these STIs has 
lagged. The syphilis spirochete, Treponema pallidum, has a unique molecular architecture and 
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the cell envelope consists of a dual membrane structure. The outer membrane is poorly 
immunogenic, lacking lipopolysaccharide and possessing few integral membrane proteins 
that could serve as surface antigenic targets for the host immune system. The strong 
antibody response observed in syphilis is principally generated by lipopolysaccharide and 
protein immunogens located in the inner membrane where they are inaccessible to this 
antibody response. To date, research on a syphilis vaccine has not progressed past the 
identification of these rare outer membrane proteins as candidate vaccine antigens. 
Development of a gonococcal vaccine has been hampered by the ability of N. gonorrhoeae to 
change surface antigens, especially Type IV pili, deficiencies in current animal models, and 
the lack of target capsular polysaccharides such as are present in N. meningitidis. Two 
candidate gonorrhea vaccines, utilizing killed whole gonococcal cells or pilus and pilus-
associated proteins, have been tested in human clinical trials but neither produced 
protection. Recent work on gonococcal vaccines has been focused on the identification of 
potential B- and T-cell epitopes for candidate antigens. The relatively low incidence of 
chancroid and donovanosis in most developed countries is mirrored by limited research 
interest towards development of vaccines for Haemophilus ducreyi and Calymmatobacterium 
granulomatis infections and there is little in the way of published work or progress on 
vaccines for these organisms. 
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